Discovery of Selective and Potent ATR Degrader for Exploration its Kinase‐Independent Functions in Acute Myeloid Leukemia Cells
Angewandte Chemie International Edition · 22.04.2024 · 63 (17)
DOI: 10.1002/anie.202318568 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 21.03.2024. Verfasst von Yubo Wang und 15 weiteren Autor:innen. Beteiligte Einrichtung: The State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Tianjin, 300071, P. R. China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Natural Science Foundation of China, nternational Science and Technology Cooperation Project of China, Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
ATR has emerged as a promising target for anti‐cancer drug development. Several potent ATR inhibitors are currently undergoing various stages of clinical trials, but none have yet received FDA approval due to unclear regulatory mechanisms. In this study, we discovered a potent and selective ATR degrader. Its kinase‐independent regulatory functions in acute myeloid leukemia (AML) cells were elucidated using this proteolysis‐targeting chimera (PROTAC) molecule as a probe. The ATR degrader, 8 i , exhibited significantly different cellular phenotypes compared to the ATR kinase inhibitor 1 . Mechanistic studies revealed that ATR deletion led to breakdown in the nuclear envelope, causing genome instability and extensive DNA damage. This would increase the expression of p53 and triggered immediately p53‐mediated apoptosis signaling pathway, which was earlier and more effective than ATR kinase inhibition. Based on these findings, the in vivo anti‐proliferative effects of ATR degrader 8 i were assessed using xenograft models. The degrader significantly inhibited the growth of AML cells in vivo, unlike the ATR inhibitor. These results suggest that the marked anti‐AML activity is regulated by the kinase‐independent functions of the ATR protein. Consequently, developing potent and selective ATR degraders could be a promising strategy for treating AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Tianjin, 300071, P. R. China.
- College of Food Science and Pharmaceutical Engineering, Zaozhuang University, Zaozhuang, 277160, China.
ORCID-Profile: Guang Yang
Förderung
- National Natural Science Foundation of China
- nternational Science and Technology Cooperation Project of China
- Natural Science Foundation of Shandong Province
- Ningbo Science and Technology Bureau under CM2025 Programme
- Shenzhen Science and Technology Foundation
Zitieren
APA
Wang, Y., Wang, R., Zhao, Y., Cao, S., Li, C., Wu, Y., Ma, L., Liu, Y., Yao, Y., Jiao, Y., Chen, Y., Liu, S., Zhang, K., Wei, M., Yang, C., & Yang, G. (2024). Discovery of Selective and Potent ATR Degrader for Exploration its Kinase‐Independent Functions in Acute Myeloid Leukemia Cells. Angewandte Chemie International Edition, 63(17). https://doi.org/10.1002/anie.202318568
Vancouver
Wang Y, Wang R, Zhao Y, Cao S, Li C, Wu Y, et al. Discovery of Selective and Potent ATR Degrader for Exploration its Kinase‐Independent Functions in Acute Myeloid Leukemia Cells. Angewandte Chemie International Edition. 2024;63(17). doi:10.1002/anie.202318568
BibTeX
@article{Wang2024,
author = {Wang, Yubo and Wang, Ruonan and Zhao, Yanli and Cao, Sheng and Li, Chen and Wu, Yanjie and Ma, Lan and Liu, Ying and Yao, Yuhong and Jiao, Yue and Chen, Yukun and Liu, Shuangwei and Zhang, Kun and Wei, Mingming and Yang, Cheng and Yang, Guang},
title = {Discovery of Selective and Potent ATR Degrader for Exploration its Kinase‐Independent Functions in Acute Myeloid Leukemia Cells},
journal = {Angewandte Chemie International Edition},
year = {2024},
volume = {63},
number = {17},
doi = {10.1002/anie.202318568}
}
EUVIMED